miR-193a-3p regulates the multi-drug resistance of bladder cancer by targeting the LOXL4 gene and the Oxidative Stress pathway

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Deng, Hui ^a   Lv, Lei ^a   Li, Yang ^b   Zhang, Cheng ^c   Meng, Fang ^a   Pu, Youguang ^a   Xiao, Jun ^d   Qian, Liting ^a   Zhao, Weidong ^a   Liu, Qi ^e   Zhang, Daming ^c   Wang, Yingwei ^c   Zhang, Hongyu ^f   He, Yinghua ^f   Zhu, Jingde ^a,f  

^a Anhui Cancer Hospital   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^d ANHUI PROVINCIAL HOSPITAL   (China)

^e HARBIN INSTITUTE OF TECHNOLOGY   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bladder cancer; Chemoresistance; LOXL4; miR 193a 3p; Oxidative stress pathway

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; MICRORNA; MICRORNA 193A 3P; PACLITAXEL; PIRARUBICIN; UNCLASSIFIED DRUG; LOXL4 PROTEIN, HUMAN; MESSENGER RNA; MIRN193 MICRORNA, HUMAN; NUCLEAR PROTEIN; OXIDOREDUCTASE; RIBONUCLEOPROTEIN; SMALL INTERFERING RNA; SRSF2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CELL CULTURE; CONTROLLED STUDY; DNA FLANKING REGION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; LOXL4 GENE; MALE; MOUSE; NONHUMAN; ONCOGENE; OXIDATIVE STRESS; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOLOGICAL MODEL; BLADDER TUMOR; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MULTIDRUG RESISTANCE; NUDE MOUSE; REPRODUCIBILITY; TUMOR CELL LINE;

MUS MUSCULUS;

AMINO ACID OXIDOREDUCTASES; ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; MODELS, BIOLOGICAL; NUCLEAR PROTEINS; OXIDATIVE STRESS; PACLITAXEL; REPRODUCIBILITY OF RESULTS; RIBONUCLEOPROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84935016143     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-234     Document Type: Article

References (52)

1. Burger M, Catto JW, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S: Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013,63(2):234-241 10.1016/j.eururo.2012.07.033
2. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 1, 23:4602-4608. 10.1200/JCO.2005.07.757
3. Chang JS, Lara PN, Pan C-X: Progress in personalizing chemotherapy for bladder cancer. Adv Urol 2012, 2012:364919.
4. Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell 1, 136:215-233. 10.1016/j.cell.2009.01.002
5. Di Leva G, Garofalo M, Croce CM: MicroRNAs in cancer. Annu Rev Pathol Mech Dis 1, 9:287-314. 10.1146/annurev-pathol-012513-104715
6. Cheng CJ, Slack FJ: The duality of oncomiR addiction in the maintenance and treatment of cancer. Cancer J (Sudbury, Mass) 1, 18:232. 10.1097/PPO.0b013e318258b75b
7. Blandino G, Fazi F, Donzelli S, Kedmi M, Sas-Chen A, Muti P, Strano S, Yarden Y: Tumor suppressor microRNAs: a novel non-coding alliance against cancer. FEBS Lett 2014,588(16):2639-2652. 10.1016/j.febslet.2014.03.033
8. Ling H, Fabbri M, Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 1, 12:847-865. 10.1038/nrd4140
9. Sethi S, Ali S, Philip PA, Sarkar FH: Clinical advances in molecular biomarkers for cancer diagnosis and therapy. Int J Mol Sci 1, 14:14771-14784. 10.3390/ijms140714771
10. Haenisch S, Cascorbi I: miRNAs as mediators of drug resistance. Epigenomics 1, 4:369-381. 10.2217/epi.12.39
11. Su S, Chang Y, Andreu-Vieyra C, Fang J, Yang Z, Han B, Lee A, Liang G: miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene 2013,32(39):4694-4701. 10.1038/onc.2012.483
12. K-i K, Imoto I, Mogi S, Omura K, Inazawa J: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 1, 68:2094-2105. 10.1158/0008-5472.CAN-07-5194
13. Heller G, Weinzierl M, Noll C, Babinsky V, Ziegler B, Altenberger C, Minichsdorfer C, Lang G, Döme B, End-Pfützenreuter A: Genome-wide miRNA expression profiling identifies miR-9-3 and miR-193a as targets for DNA Methylation in non-small cell lung cancers. Clin Cancer Res 1, 18:1619-1629. 10.1158/1078-0432.CCR-11-2450
14. Avci CB, Harman E, Dodurga Y, Susluer SY, Gunduz C: Therapeutic potential of an anti-diabetic drug, metformin: alteration of miRNA expression in prostate cancer cells. Asian Pac J Cancer Prev 1, 14:765-768. 10.7314/APJCP.2013.14.2.765
15. Tahiri A, Leivonen SK, Luders T, Steinfeld I, Ragle Aure M, Geisler J, Makela R, Nord S, Riis ML, Yakhini Z, Kleivi Sahlberg K, Børresen-Dale AL, Perälä M, Bukholm IR, Kristensen VN: Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 1, 35:76-85. 10.1093/carcin/bgt333
16. Chen D, Cabay RJ, Jin Y, Wang A, Lu Y, Shah-Khan M, Zhou X: MicroRNA deregulations in head and neck squamous cell carcinomas. J Oral Maxillofac Res 2013, 4:e2.
17. Yong FL, Law CW, Wang CW: Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 1, 13:280. 10.1186/1471-2407-13-280
18. Gao X, Lin J, Li Y, Gao L, Wang X, Wang W, Kang H, Yan G, Wang L, Yu L: MicroRNA-193a represses c-kit expression and functions as a methylation-silenced tumor suppressor in acute myeloid leukemia. Oncogene 1, 30:3416-3428. 10.1038/onc.2011.62
19. Li Y, Gao L, Luo X, Wang L, Gao X, Wang W, Sun J, Dou L, Li J, Xu C: Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t (8; 21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway. Blood 1, 121:499-509. 10.1182/blood-2012-07-444729
20. Iliopoulos D, Rotem A, Struhl K: Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res 1, 71:5144-5153. 10.1158/0008-5472.CAN-11-0425
21. Noh H, Hong S, Dong Z, Pan ZK, Jing Q, Huang S: Impaired microRNA processing facilitates breast cancer cell invasion by upregulating urokinase-type plasminogen activator expression. Genes Cancer 1, 2:140-150. 10.1177/1947601911408888
22. Uhlmann S, Mannsperger H, Zhang JD, Horvat EÁ, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K: Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol 2012, 8:570.
23. Nakano H, Yamada Y, Miyazawa T, Yoshida T: Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol 2013, 42:1875-1882.
24. Salvi A, Conde I, Abeni E, Arici B, Grossi I, Specchia C, Portolani N, Barlati S, De Petro G: Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Mol Cancer 2013, 12:162.
25. Wang J, Yang B, Han L, Li X, Tao H, Zhang S, Hu Y: Demethylation of miR-9-3 and miR-193a genes suppresses proliferation and promotes apoptosis in non-small cell lung cancer cell lines. Cell Physiol Biochem 1, 32:1707-1719. 10.1159/000356605
26. Kwon JE, Kim BY, Kwak SY, Bae IH, Han YH: Ionizing radiation-inducible microRNA miR-193a-3p induces apoptosis by directly targeting Mcl-1. Apoptosis 1, 18:896-909. 10.1007/s10495-013-0841-7
27. Yu T, Li J, Yan M, Liu L, Lin H, Zhao F, Sun L, Zhang Y, Cui Y, Zhang F, Li J, He X, Yao M: MicroRNA-193a-3p and -5p suppress the metastasis of human non-small-cell lung cancer by downregulating the ERBB4/PIK3R3/mTOR/S6K2 signaling pathway. Oncogene 2014. doi:10.1038/onc.2013.574
28. Santarpia L, Calin GA, Adam L, Ye L, Fusco A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C: A miRNA signature associated with human metastatic medullary thyroid carcinoma. Endocr Relat Cancer 1, 20:809-823. 10.1530/ERC-13-0357
29. Ma K, He Y, Zhang H, Fei Q, Niu D, Wang D, Ding X, Xu H, Chen X, Zhu J: DNA methylation-regulated miR-193a-3p dictates resistance of hepatocellular carcinoma to 5-fluorouracil via repression of SRSF2 expression. J Biol Chem 1, 287:5639-5649. 10.1074/jbc.M111.291229
30. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP: The impact of microRNAs on protein output. Nature 1, 455:64-71. 10.1038/nature07242
31. Zhao Y, Lin J, Xu B, Hu S, Zhang X, Wu L: MicroRNA-mediated repression of nonsense mRNAs. 2014.
32. Bloom DA, Jaiswal AK: Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from INrf1, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD (P) H: quinone oxidoreductase-1 gene expression. J Biol Chem 2003, 278:44675-44682. 10.1074/jbc.M307633200
33. Sarkar S, Dutta D, Samanta SK, Bhattacharya K, Pal BC, Li J, Datta K, Mandal C, Mandal C: Oxidative inhibition of Hsp90 disrupts the super-chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo. Int J Cancer 1, 132:695-706. 10.1002/ijc.27687
34. Bosch-Presegué L, Raurell-Vila H, Marazuela-Duque A, Kane-Goldsmith N, Valle A, Oliver J, Serrano L, Vaquero A: Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection. Mol Cell 1, 42:210-223. 10.1016/j.molcel.2011.02.034
35. Scola N, Goeroegh T: LOXL4 as a selective molecular marker in primary and metastatic head/neck carcinoma. Anticancer Res 2010, 30:4567-4571.
36. Weise JB, Rudolph P, Heiser A, Kruse M-L, Hedderich J, Cordes C, Hoffmann M, Brant O, Ambrosch P, Csiszar K: LOXL4 is a selectively expressed candidate diagnostic antigen in head and neck cancer. Eur J Cancer 1, 44:1323-1331. 10.1016/j.ejca.2008.03.026
37. Sebban S, Golan-Gerstl R, Karni R, Vaksman O, Davidson B, Reich R: Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer. Clin Exp Metastasis 1, 30:103-117. 10.1007/s10585-012-9514-0
38. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, Hendrix MJ: A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002, 62:4478-4483.
39. Görögh T, Weise J, Holtmeier C, Rudolph P, Hedderich J, Gottschlich S, Hoffmann M, Ambrosch P, Csiszar K: Selective upregulation and amplification of the lysyl oxidase like-4 (LOXL4) gene in head and neck squamous cell carcinoma. J Pathol 1, 212:74-82. 10.1002/path.2137
40. Weise JB, Csiszar K, Gottschlich S, Hoffmann M, Schmidt A, Weingartz U, Adamzik I, Heiser A, Kabelitz D, Ambrosch P: Vaccination strategy to target lysyl oxidase-like 4 in dendritic cell based immunotherapy for head and neck cancer. Int J Oncol 2008, 32:317-322.
41. Kim Y, Roh S, Park J-Y, Kim Y, Cho DH, Kim JC: Differential expression of the LOX family genes in human colorectal adenocarcinomas. Oncol Rep 2009, 22:799-804.
42. Wu G, Guo Z, Chang X, Kim MS, Nagpal JK, Liu J, Maki JM, Kivirikko KI, Ethier SP, Trink B: LOXL1 and LOXL4 are epigenetically silenced and can inhibit ras/extracellular signal-regulated kinase signaling pathway in human bladder cancer. Cancer Res 1, 67:4123-4129. 10.1158/0008-5472.CAN-07-0012
43. Jaramillo MC, Zhang DD: The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev 1, 27:2179-2191. 10.1101/gad.225680.113
44. Soler-López M, Badiola N, Zanzoni A, Aloy P: Towards Alzheimer's root cause: ECSIT as an integrating hub between oxidative stress, inflammation and mitochondrial dysfunction. Bioessays 1, 34:532-541. 10.1002/bies.201100193
45. Türei D, Papp D, Fazekas D, Földvári-Nagy L, Módos D, Lenti K, Csermely P, Korcsmáros T: NRF2-ome: an integrated web resource to discover protein interaction and regulatory networks of NRF2. Oxid Med Cell Longev 2013, 2013:737591.
46. Papp D, Lenti K, Módos D, Fazekas D, Dúl Z, Türei D, Földvári-Nagy L, Nussinov R, Csermely P, Korcsmáros T: The NRF2-related interactome and regulome contain multifunctional proteins and fine-tuned autoregulatory loops. FEBS Lett 1, 586:1795-1802. 10.1016/j.febslet.2012.05.016
47. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, Happel C, Shyr C, Wakabayashi N, Kensler TW, Wasserman WW: Global mapping of binding sites for Nrf2 identifies novel targets in cell survival response through ChIP-Seq profiling and network analysis. Nucleic Acids Res 1, 38:5718-5734. 10.1093/nar/gkq212
48. Sandelin A, Alkema W, Engström P, Wasserman WW, Lenhard B: JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res 1, 32:D91-D94. 10.1093/nar/gkh012
49. Gañán-Gómez I, Wei Y, Yang H, Boyano-Adánez MC, García-Manero G: Oncogenic functions of the transcription factor Nrf2. Free Radic Biol Med 2013, 65:750-764.
50. Xu B, He Y, Wu X, Luo C, Liu A, Zhang J: Exploration of the correlations between interferon-gamma in patient serum and HEPACAM in bladder transitional cell carcinoma, and the interferon-gamma mechanism Inhibiting BIU-87 proliferation. J Urol 1, 188:1346-1353. 10.1016/j.juro.2012.06.005
51. Andrisano V, Bartolini M, Gotti R, Cavrini V, Felix G: Determination of inhibitors' potency (IC50) by a direct high-performance liquid chromatographic method on an immobilised acetylcholinesterase column. J Chromatogr B Biomed Sci Appl 1, 753:375-383. 10.1016/S0378-4347(00)00571-5
52. Ohashi K, Marion PL, Nakai H, Meuse L, Cullen JM, Bordier BB, Schwall R, Greenberg HB, Glenn JS, Kay MA: Sustained survival of human hepatocytes in mice: a model for in vivo infection with human hepatitis B and hepatitis delta viruses. Nat Med 1, 6:327-331. 10.1038/73187